Current evidence is not sufficient to support levosimendan as superior to dobutamine or as an optimal adjunct in severe sepsis and septic shock. More large-scale randomised trials are necessary to validate levosimendan use in sepsis.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2018) studied this question.